Form 4: Director Nathan Fischel Acquires Stereotaxis Stock

Sentiment:

Insider Transaction


Director Nathan Fischel acquired 43,103 restricted share units of Stereotaxis, Inc. on July 1, 2026, as part of a grant.

Summary

  • Nathan Fischel, a Director and 10% owner of Stereotaxis, Inc., was granted 43,103 restricted share units (RSUs) on July 1, 2026.
  • Each RSU represents the right to receive one share of common stock.
  • These RSUs vest on the earliest of the fifth anniversary of the award date, the termination of Fischel's board service, or a Change of Control.
  • Following this transaction, Fischel beneficially owns 720,775 shares of common stock directly, and an additional 13,680,554 shares indirectly through funds managed by DAFNA Capital Management LLC, where he serves as CEO.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of equity compensation to a director rather than a significant change in ownership or company performance.

Positives

  • Director Fischel's acquisition of RSUs indicates continued commitment and alignment with the company's performance.
  • The grant of RSUs is a common incentive for directors, aligning their interests with long-term shareholder value.
  • Fischel's significant indirect beneficial ownership suggests a substantial stake in the company's success.

Risks

  • The vesting of RSUs is contingent on several factors, including continued service and potential Change of Control events, which introduce uncertainty.
  • The indirect ownership through DAFNA Capital Management LLC means that the ultimate control and decision-making for those shares may be subject to the fund's investment strategy and governance.

Future Outlook

The vesting schedule for the restricted share units is tied to future events, including the fifth anniversary of the award, termination of board service, or a Change of Control, indicating a long-term perspective for these awards.

Industry Context

StockSavvy.ai notes that insider grants of equity, such as restricted share units, are standard practice in the medical technology sector to incentivize leadership and align executive interests with shareholder value over the long term.

Stakeholder Impact

  • Shareholders: The grant of RSUs to Director Fischel aligns his interests with long-term shareholder value, potentially leading to decisions that benefit the company's stock performance.
  • Employees: While not directly impacting employees, such grants are part of the overall compensation structure for leadership, which can indirectly influence company culture and strategic direction.

Next Steps

  • Vesting of restricted share units on the earliest of the fifth anniversary of the award, termination of board service, or a Change of Control.

Key Dates

DateDescription
07/01/2026Transaction Date for the grant of restricted share units and earliest transaction date.
07/01/2026Effective date of the grant of restricted share units.

Keywords

Stereotaxis, STXS, Form 4, Insider Transaction, Restricted Share Units, Director Compensation, Beneficial Ownership, Nathan Fischel, DAFNA Capital Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.